Thursday, December 05, 2024 10:03:19 AM
ask yourself this question.... with all these bio stocks going up from 1-2.00 to 10-15.00 on way lesser (not as vague) news... why does no one want this one at a dollar? You know why... you can say it..
Recent RNXT News
- Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/09/2026 02:19:11 PM
- RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum • GlobeNewswire Inc. • 04/08/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:00:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 12:00:02 AM
- RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 • GlobeNewswire Inc. • 04/01/2026 06:20:16 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/31/2026 08:19:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:38:46 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:34:03 PM
- RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/30/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 11:00:10 AM
- RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment • GlobeNewswire Inc. • 03/26/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 01:16:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/25/2026 01:16:41 AM
- RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement • GlobeNewswire Inc. • 03/23/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:00:38 AM
- RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET • GlobeNewswire Inc. • 03/20/2026 12:30:00 PM
- RenovoRx Announces $10 Million at Market Private Placement • GlobeNewswire Inc. • 03/18/2026 12:35:18 PM
- RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum • GlobeNewswire Inc. • 02/27/2026 01:30:00 PM
- RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting • GlobeNewswire Inc. • 02/26/2026 01:30:00 PM
- RenovoRx Establishes RenovoCath® Medical Advisory Board • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 12:00:43 PM
- RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer • GlobeNewswire Inc. • 02/05/2026 01:30:00 PM
- RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting • GlobeNewswire Inc. • 02/04/2026 01:30:00 PM
